» Articles » PMID: 24454733

Deriving a Mutation Index of Carcinogenicity Using Protein Structure and Protein Interfaces

Overview
Journal PLoS One
Date 2014 Jan 24
PMID 24454733
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

With the advent of Next Generation Sequencing the identification of mutations in the genomes of healthy and diseased tissues has become commonplace. While much progress has been made to elucidate the aetiology of disease processes in cancer, the contributions to disease that many individual mutations make remain to be characterised and their downstream consequences on cancer phenotypes remain to be understood. Missense mutations commonly occur in cancers and their consequences remain challenging to predict. However, this knowledge is becoming more vital, for both assessing disease progression and for stratifying drug treatment regimes. Coupled with structural data, comprehensive genomic databases of mutations such as the 1000 Genomes project and COSMIC give an opportunity to investigate general principles of how cancer mutations disrupt proteins and their interactions at the molecular and network level. We describe a comprehensive comparison of cancer and neutral missense mutations; by combining features derived from structural and interface properties we have developed a carcinogenicity predictor, InCa (Index of Carcinogenicity). Upon comparison with other methods, we observe that InCa can predict mutations that might not be detected by other methods. We also discuss general limitations shared by all predictors that attempt to predict driver mutations and discuss how this could impact high-throughput predictions. A web interface to a server implementation is publicly available at http://inca.icr.ac.uk/.

Citing Articles

3DVizSNP: a tool for rapidly visualizing missense mutations identified in high throughput experiments in iCn3D.

Sierk M, Ratnayake S, Wagle M, Chen B, Park B, Wang J BMC Bioinformatics. 2023; 24(1):244.

PMID: 37296383 PMC: 10251577. DOI: 10.1186/s12859-023-05370-5.


Dynamic coupling of residues within proteins as a mechanistic foundation of many enigmatic pathogenic missense variants.

Ose N, Butler B, Kumar A, Kazan I, Sanderford M, Kumar S PLoS Comput Biol. 2022; 18(4):e1010006.

PMID: 35389981 PMC: 9017885. DOI: 10.1371/journal.pcbi.1010006.


Proteogenomic Analysis of Protein Sequence Alterations in Breast Cancer Cells.

Lazar I, Karcini A, Ahuja S, Estrada-Palma C Sci Rep. 2019; 9(1):10381.

PMID: 31316139 PMC: 6637242. DOI: 10.1038/s41598-019-46897-z.


Protein interaction disruption in cancer.

Ruffalo M, Bar-Joseph Z BMC Cancer. 2019; 19(1):370.

PMID: 31014259 PMC: 6823625. DOI: 10.1186/s12885-019-5532-5.


A CATH domain functional family based approach to identify putative cancer driver genes and driver mutations.

Ashford P, Pang C, Moya-Garcia A, Adeyelu T, Orengo C Sci Rep. 2019; 9(1):263.

PMID: 30670742 PMC: 6343001. DOI: 10.1038/s41598-018-36401-4.


References
1.
Xu D, Tsai C, Nussinov R . Hydrogen bonds and salt bridges across protein-protein interfaces. Protein Eng. 1998; 10(9):999-1012. DOI: 10.1093/protein/10.9.999. View

2.
Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

3.
Bass A, Lawrence M, Brace L, Ramos A, Drier Y, Cibulskis K . Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011; 43(10):964-968. PMC: 3802528. DOI: 10.1038/ng.936. View

4.
MacArthur M, Thornton J . Influence of proline residues on protein conformation. J Mol Biol. 1991; 218(2):397-412. DOI: 10.1016/0022-2836(91)90721-h. View

5.
Izarzugaza J, Redfern O, Orengo C, Valencia A . Cancer-associated mutations are preferentially distributed in protein kinase functional sites. Proteins. 2009; 77(4):892-903. DOI: 10.1002/prot.22512. View